Idis is the global market leader in providing access to unlicensed medicines in over 100 countries. Smith Square Partners acted as independent adviser to the Board on the acquisition of Idis Group Holdings Ltd and Vendor Placing
Smith Square Partners
Advised in the sale of
Idis Group Holdings Ltd
to